[Federal Register Volume 62, Number 175 (Wednesday, September 10, 1997)] [Notices] [Pages 47676-47677] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 97-23900] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: For Nucleic Acid-Based Vaccines and Therapeutics AGENCY: National Institutes of Health, Public Health Service, DHHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive license in the United States to practice the invention embodied in U.S. Patent Application Number 08/ 286,730 entitled, ``Liposomal Delivery System for Nucleic Acids,'' and its Continuation-In-Part U.S. Patent Application Serial Number 08/ 522,246, and all related foreign filings (PCT/US95/09867), invented by Alain Thierry formerly of the National Cancer Institute, to Biovector Therapeutics, S.A of Labage, France. The patent rights in these inventions have been assigned to the United States of America. DATES: Only written comments and/or applications for a license which are received by NIH on or before December 9, 1997 will be considered. ADDRESSES: Requests for copies of the subject issued patent and pending patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Mr. Larry M. Tiffany, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852; Telephone: (301) 496-7056, ext. 206; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the pending patent applications. SUPPLEMENTARY INFORMATION: The present invention relates to a liposome composition comprising a bi- or multi-layered membrane surrounding an internal aqueous liposome comprising at least one cationic lipopolyamine and at least one neutral lipid provided in a molar ratio range, said ratio from about .02:1 to 2:1. In addition to the pending composition claims there are also pending rights to methods of preparing the liposome composition, pharmaceutical compositions including the liposome and methods of introducing nucleic acids into cells using the liposome. This invention is advantageous over alternative lipid preparations due to its ability to more [[Page 47677]] easily form liposomes at physiological temperatures and pH hence making it potentially more stable in-vivo. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 90 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. The field of use would be limited to nucleic acid-based vaccines and therapeutics. Applications for a license to the field of use described in this Notice will be treated as objections to the contemplated license. Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act, 5 U.S.C. 552. Dated: September 2, 1997. Barbara M. McGarey, Deputy Director, Office of Technology Transfer. [FR Doc. 97-23900 Filed 9-9-97; 8:45 am] BILLING CODE 4140-01-P